Literature DB >> 18082269

Increasing incidence of Candida parapsilosis candidemia with caspofungin usage.

Graeme N Forrest1, Elizabeth Weekes, Jennifer K Johnson.   

Abstract

OBJECTIVES: To determine the impact on the change in epidemiology of Candida species at our institution since the introduction of caspofungin.
METHODS: A 5-year retrospective review of all candidemia at a major tertiary care center. Only one episode of candidemia per patient per admission was counted. All antifungal defined daily doses were also collected in this same time period. Regression analysis was performed on the data and correlation statistics among antifungal use and Candida species were assessed using a Pearson correlation analysis.
RESULTS: There were 469 individual episodes of candidemia between fiscal year 2002 and 2006 with the rate increasing every year. On regression analysis there was a significant increase in Candida parapsilosis candidemia (R(2)=0.90, p=0.02) and significant increase in caspofungin usage (R(2)=0.80, p<0.01), with a correspondingly significant decline in conventional (R(2)=-0.77, p<0.01) and lipid amphotericin B (R(2)=-0.95, p<0.05) usage. We found correlations between increased caspofungin usage (R(2)=0.94, p=0.017) and increased C. parapsilosis candidemia and decreased Candida tropicalis candidemia (R(2)=0.92, p<0.05) and a trend towards decreased Candida glabrata (R(2)=0.64, p=0.1).
CONCLUSIONS: We showed significant correlations between increased caspofungin usage and an increased incidence of C. parapsilosis candidemia and reduction in C. tropicalis candidemia, with a trend towards less C. glabrata candidemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18082269     DOI: 10.1016/j.jinf.2007.10.014

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  34 in total

1.  Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.

Authors:  Olivier Lortholary; Marie Desnos-Ollivier; Karine Sitbon; Arnaud Fontanet; Stéphane Bretagne; Françoise Dromer
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  On track to limit antifungal overuse!

Authors:  Philippe Eggimann; Frédéric Lamoth; Oscar Marchetti
Journal:  Intensive Care Med       Date:  2009-02-11       Impact factor: 17.440

3.  Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature.

Authors:  Maria Siopi; Aikaterini Tarpatzi; Eleni Kalogeropoulou; Sofia Damianidou; Alexandra Vasilakopoulou; Sophia Vourli; Spyros Pournaras; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France.

Authors:  Elodie Blanchard; Olivier Lortholary; Karine Boukris-Sitbon; Marie Desnos-Ollivier; Françoise Dromer; Didier Guillemot
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

5.  Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media.

Authors:  Maiken Cavling Arendrup; Guillermo Garcia-Effron; Cornelia Lass-Flörl; Alicia Gomez Lopez; Juan-Luis Rodriguez-Tudela; Manuel Cuenca-Estrella; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

Review 6.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

7.  Increase in Candida parapsilosis fungemia in critical care units: a 6-years study.

Authors:  Elif Sahin Horasan; Gülden Ersöz; Musa Göksu; Feza Otag; Ahmet Oner Kurt; Sevim Karaçorlu; Ali Kaya
Journal:  Mycopathologia       Date:  2010-06-04       Impact factor: 2.574

8.  In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.

Authors:  D Andes; D J Diekema; M A Pfaller; J Bohrmuller; K Marchillo; A Lepak
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

Review 9.  Candida parapsilosis, an emerging fungal pathogen.

Authors:  David Trofa; Attila Gácser; Joshua D Nosanchuk
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

Review 10.  Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis.

Authors:  Mohan Pammi; Linda Holland; Geraldine Butler; Attila Gacser; Joseph M Bliss
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.